New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 25, 2024 - IntraBio announced the FDA approval of Aqneursa (levacetylleucine), for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.
Download PDF
Return to publications
